
|Videos|October 10, 2016
How Can Access to PCSK9 Inhibitors be Improved?
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Advertisement
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
2
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
3
High Burden of PCV21 Strains in Norway Shows Need for Effective US Vaccination Strategies
4
COVID-19 Vaccine Before, During Pregnancy Lowers Disease Risks and Preterm Births
5










































































































































































































